🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06489080
Recruiting Observational

Survival and cArdiovascular eVents in Patients With Acute Myocardial Infarction

NCT06489080 · tracked via the Priya Life Science China tracker
Sponsor
Peking University First Hospital
Phase
Observational
Started
2024-03-01
Last updated
2024-07-05

Condition(s) studied

Acute Myocardial InfarctionCoronary Artery Disease

Study summary

This prospective and prospective cohort study aims to establish a long-term follow-up cohort of patients with acute myocardial infarction, and combine multi-omics studies, wearable devices, artificial intelligence technology, etc., to describe the clinical characteristics of patients with acute myocardial infarction and the changing trend of treatment strategies, and analyze the related influencing factors. Explore new biomarkers and indicators affecting recurrent cardiovascular events for accurate risk stratification and risk prediction; To evaluate the factors affecting lifestyle intervention, drug efficacy and safety, and their impact on outcome, and improve chronic disease management mode, in order to improve the quality of life and prognosis of patients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Acute myocardial infarction is diagnosed meets the universal definition of acute myocardial infarction Exclusion Criteria: * Did not agree to participate in the study

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Division of Cardiology, Peking University First Hospital Beijing Beijing Municipality Recruiting

More Peking University First Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06489080 on ClinicalTrials.gov ↗ ← All trials in China